Caribou Biosciences, Inc. (CRBU)
Largest Insider Buys in Sector
CRBU Stock Price History Chart
CRBU Stock Performance
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Insider Activity of Caribou Biosciences, Inc.
Over the last 12 months, insiders at Caribou Biosciences, Inc. have bought $0 and sold $0 worth of Caribou Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Caribou Biosciences, Inc. have bought $299,343 and sold $628,685 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,387 shares for transaction amount of $29,553 was made by Fischesser Ryan (VP of Finance and Controller) on 2022‑01‑11.
List of Insider Buy and Sell Transactions, Caribou Biosciences, Inc.
| 2023-01-19 | Sale | Chief Medical Officer | 5,627 0.0093% | $6.31 | $35,506 | -16.06% | ||
| 2022-10-06 | Sale | VP of Finance and Controller | 10,000 0.0162% | $10.80 | $107,958 | -43.36% | ||
| 2022-08-25 | Sale | Chief Scientific Officer | 43,248 0.0707% | $11.22 | $485,221 | -41.04% | ||
| 2022-01-11 | VP of Finance and Controller | 7,387 0.0038% | $4.00 | $29,553 | -29.34% | |||
| 2021-12-20 | VP of Finance and Controller | 1,136 0.0003% | $2.69 | $3,056 | -38.62% | |||
| 2021-12-07 | Chief Legal Officer | 6,127 0.0015% | $2.69 | $16,482 | -50.11% | |||
| 2021-10-20 | Chief Legal Officer | 9,219 0.0021% | $2.69 | $24,799 | -50.25% | |||
| 2021-10-12 | Chief Scientific Officer | 114,860 0.0179% | $1.92 | $220,757 | -51.66% | |||
| 2021-10-11 | VP of Finance and Controller | 1,746 0.0004% | $2.69 | $4,697 | -48.53% |
Insider Historical Profitability
| MCCLUNG BARBARA G | Chief Legal Officer | 348971 0.3854% | $1.52 | 2 | 0 | <0.0001% |
| Kanner Steven | Chief Scientific Officer | 302059 0.3336% | $1.52 | 1 | 1 | <0.0001% |
| Fischesser Ryan | VP of Finance and Controller | 110366 0.1219% | $1.52 | 3 | 1 | <0.0001% |
| Rizvi Syed Ali-aamir | Chief Medical Officer | 59373 0.0656% | $1.52 | 0 | 1 |
Institutional Investor Ownership
| BlackRock | $36.01M | 7.76 | 7.01M | -0.9% | -$325,906.84 | <0.01 | |
| PFM Health Sciences | $33.32M | 7.18 | 6.48M | +0.04% | +$12,880.84 | 0.92 | |
| State Street | $32.63M | 7.03 | 6.35M | +23.98% | +$6.31M | <0.01 | |
| Avidity Partners Management Lp | $29.74M | 6.41 | 5.79M | -9.04% | -$2.95M | 1.13 | |
| The Vanguard Group | $21.13M | 4.55 | 4.11M | +3.75% | +$764,580.13 | <0.0001 | |
| Point72 Asset Management | $18.43M | 3.97 | 3.59M | +1.81% | +$327,119.89 | 0.03 | |
| Alkeon Capital Management Llc | $14.1M | 3.04 | 2.74M | -11.88% | -$1.9M | 0.08 | |
| Elmwood Wealth | $12.15M | 2.62 | 2.36M | <0.01% | -$102.80 | 6.05 | |
| Paradigm BioCapital Advisors LP | $11.17M | 2.41 | 2.17M | -25.69% | -$3.86M | 0.41 | |
| Dimensional Fund Advisors | $10.73M | 2.31 | 2.09M | +54.51% | +$3.78M | <0.01 | |
| Geode Capital Management | $9.47M | 2.04 | 1.84M | +2.65% | +$244,363.66 | <0.01 | |
| Schonfeld Group | $9.47M | 2.04 | 1.84M | New | +$9.47M | 0.05 | |
| Fidelity Investments | $7.43M | 1.6 | 1.45M | +0.04% | +$3,012.04 | <0.0001 | |
| Candriam S C A | $5.89M | 1.27 | 1.15M | +33.14% | +$1.47M | 0.04 | |
| Bank of America | $5.74M | 1.24 | 1.12M | -29.9% | -$2.45M | <0.01 | |
| Kynam Capital Management Lp | $5.49M | 1.18 | 1.07M | 0% | +$0 | 0.07 | |
| Fil Ltd | $4.42M | 0.95 | 860,666 | 0% | +$0 | <0.01 | |
| Rokos Capital Management | $4.3M | 0.93 | 840,630 | 0% | +$0 | 0.11 | |
| Charles Schwab | $4.24M | 0.91 | 824,657 | +2.09% | +$86,855.72 | <0.01 | |
| Northern Trust | $3.77M | 0.81 | 734,265 | -3.05% | -$118,718.58 | <0.01 | |
| Maverick Capital Ltd | $3.35M | 0.72 | 652,542 | 0% | +$0 | 0.07 | |
| Goldman Sachs | $3.1M | 0.67 | 602,902 | -8.66% | -$293,689.39 | <0.01 | |
| JPMorgan Chase | $2.82M | 0.61 | 549,053 | -4.84% | -$143,565.37 | <0.0001 | |
| Rafferty Asset Management Llc | $2.78M | 0.6 | 541,449 | +42.04% | +$823,690.18 | 0.01 | |
| Citadel Advisors LLC | $2.71M | 0.58 | 526,914 | New | +$2.71M | <0.01 | |
| 72 Investment Holdings Llc | $2.44M | 0.53 | 474,067 | 0% | +$0 | 3.63 | |
| Citigroup | $2.41M | 0.52 | 469,520 | +190.33% | +$1.58M | <0.01 | |
| Wellington Management Company | $2.27M | 0.49 | 441,806 | +40.67% | +$656,511.69 | <0.0001 | |
| Morgan Stanley | $2.13M | 0.46 | 414,497 | -62.48% | -$3.55M | <0.0001 | |
| UBS | $2.1M | 0.45 | 408,275 | +25.04% | +$420,174.54 | <0.01 | |
| Marshall Wace | $1.89M | 0.41 | 368,257 | +537.89% | +$1.6M | <0.01 | |
| Readystate Asset Management Lp | $1.77M | 0.38 | 344,495 | New | +$1.77M | 0.1 | |
| BNY Mellon | $1.39M | 0.3 | 270,175 | -8.49% | -$128,803.21 | <0.0001 | |
| Nuveen | $1.38M | 0.3 | 267,735 | 0% | +$0 | <0.0001 | |
| ROYCE & ASSOCIATES INC | $1.33M | 0.29 | 258,928 | +2.3% | +$29,945.64 | 0.01 | |
| Westwood Holdings Group, Inc. | $1.29M | 0.28 | 251,467 | -9.29% | -$132,340.36 | 0.01 | |
| Woodline Partners LP | $1.22M | 0.26 | 237,277 | -79.2% | -$4.64M | 0.01 | |
| Mirae Asset Global Investments Co Ltd | $1.1M | 0.26 | 230,192 | +32.59% | +$269,565.21 | <0.01 | |
| Two Sigma | $1.18M | 0.25 | 229,747 | -54.47% | -$1.41M | <0.01 | |
| Bruce Co Inc | $1.03M | 0.22 | 200,000 | 0% | +$0 | 0.43 | |
| Resonant Capital Advisors | $946,778.00 | 0.2 | 184,198 | 0% | +$0 | 0.09 | |
| Standard Life | $932,843.00 | 0.2 | 181,487 | 0% | +$0 | <0.01 | |
| Squarepoint Ops LLC | $873,409.00 | 0.19 | 169,924 | +83.37% | +$397,095.68 | <0.01 | |
| Balyasny Asset Management Llc | $836,191.00 | 0.18 | 162,683 | New | +$836,191.00 | <0.01 | |
| ExodusPoint Capital Management, LP | $815,000.00 | 0.18 | 158,612 | New | +$815,000.00 | 0.01 | |
| Acadian Asset Management | $802,000.00 | 0.17 | 156,238 | +8.26% | +$61,192.81 | <0.01 | |
| Adage Capital Partners Gp L L C | $791,216.00 | 0.17 | 153,933 | -24.52% | -$257,000.12 | <0.01 | |
| DekaBank | $666,000.00 | 0.14 | 130,000 | 0% | +$0 | <0.01 | |
| Alyeska Investment Group L P | $642,500.00 | 0.14 | 125,000 | 0% | +$0 | <0.01 | |
| RhumbLine Advisers | $629,728.00 | 0.14 | 122,517 | +2.9% | +$17,758.44 | <0.01 |